Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$10.30 USD
+0.10 (0.96%)
Updated Jun 4, 2024 03:34 PM ET
After-Market: $10.47 +0.17 (1.67%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Pieris Pharmaceuticals, Inc. [PIRS]
Reports for Purchase
Showing records 81 - 91 ( 91 total )
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage of Pieris Pharmaceuticals with a Buy rating and 12- month target price of $7/share
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J